Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Glueck, Charles J.
Funding for this research was provided by:
Lipoprotein Research Fund of the Jewish Hospital of Cincinnati